We care for

our volunteers our employees our patients our development and education our environment our community your projects your development you our volunteers

Who we are?

Biokinetica Early Phase Institute is a clinical research company with its own Phase 1 / Clinical Pharmacology Unit located in Warsaw area, Poland, with a Head Office in Berlin and and Operational Hub in Warsaw.

Biokinetica Gmbh is a German company with head office in Berlin specialized in performing Phase I & PROOF OF CONCEPT clinical trials with healthy volunteers and patients.

Biokinetica conducts clinical trials at its own state-of-the-art Phase 1 Unit dedicated to conduct early phase research studies with full hospital infrastructure. The 50-bed hospital is located 25 minute’s drive form the Warsaw Airport Okecie and city downtown.

Biokinetica is a reference Phase 1 Unit for the world’s global CROs and  Pharma &  Biotech companies.

Our Phase I Clinical Pharmacology Unit of 2,500 sq.m is fully equipped, and it assures the following:

24-hour medical coverage, 7 days a week

Ambulatory rooms

In-house pharmacy

On-site Fully Equipped Modern Operating Room (incl. ability to perform study procedures in full anasthesia)

The largest in Poland database with HV and patients

Subjects’ rooms with hospital beds (50 beds in total)

In-house laboratory

State of the art medical equipment, incl. emergency equipment, medical gases, etc.

Emergency Room and Intensive Care Unit located in house

>70 highly qualified and experienced staff (physicians, nurses, laboratory technicians, pharmacists, study coordinators, QA/QC, etc.)

Our team’s experience

Type of study / Therapeutic area Phase
First-In-Man study Phase I
Biosimilars Phase I
Drug-Drug Interaction Phase I
Bioequivalence studies Phase I
Cardiovascular Phase I-II
Oncology Phase I-II
CNS Phase I-II
Respiratory Phase I-II
Infections, virology Phase II
Gynecology Phase I

Development priorities

  • The invention of the only such First-phase Research Center in Mazovia, specializing in both biosimilarity studies and innovative studies such as immunotherapies. Biosimilars have the potential to increase access and provide lower cost options for therapy as patent protection for some of the most widely used cures begins to expire.
  • Creating a team of top medical specialists ready to break new ground in innovative technologies and strategies.
  • Bringing together researchers from around the world, giving them the opportunity to develop more and better treatments to help the many people who live without access to good enough care or treatment.
  • Provide exceptional standards for study sponsors to maintain a long-term partnership.

The numbers
speak for us








project and research